HC Wainwright Issues Negative Estimate for SLNO Earnings

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Equities research analysts at HC Wainwright cut their Q3 2026 EPS estimates for shares of Soleno Therapeutics in a research report issued to clients and investors on Wednesday, March 4th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of $1.15 per share for the quarter, down from their previous estimate of $1.24. HC Wainwright has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Soleno Therapeutics’ Q4 2026 earnings at $1.56 EPS, FY2026 earnings at $4.65 EPS, Q1 2027 earnings at $1.58 EPS, Q2 2027 earnings at $1.78 EPS, Q3 2027 earnings at $1.96 EPS and Q4 2027 earnings at $2.18 EPS.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Soleno Therapeutics in a report on Thursday, January 22nd. Wolfe Research set a $60.00 price target on Soleno Therapeutics in a research note on Monday, January 12th. Robert W. Baird set a $107.00 price target on Soleno Therapeutics in a report on Tuesday, January 13th. Wall Street Zen downgraded shares of Soleno Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Finally, Wells Fargo & Company decreased their target price on shares of Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating on the stock in a research report on Friday, February 27th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Soleno Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $106.85.

Soleno Therapeutics Stock Up 1.2%

SLNO stock opened at $38.57 on Friday. The stock has a market capitalization of $1.99 billion, a P/E ratio of 167.70 and a beta of -3.16. The company has a debt-to-equity ratio of 0.11, a quick ratio of 5.55 and a current ratio of 5.80. Soleno Therapeutics has a one year low of $32.63 and a one year high of $90.32. The company has a 50 day moving average price of $41.77 and a two-hundred day moving average price of $52.42.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.16. The firm had revenue of $91.73 million for the quarter, compared to analysts’ expectations of $88.55 million.

Hedge Funds Weigh In On Soleno Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Raymond James Financial Inc. acquired a new stake in Soleno Therapeutics during the 2nd quarter worth approximately $25,000. Danske Bank A S acquired a new stake in shares of Soleno Therapeutics in the third quarter worth $27,000. Nisa Investment Advisors LLC raised its stake in shares of Soleno Therapeutics by 287.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 539 shares of the company’s stock valued at $45,000 after acquiring an additional 400 shares during the period. Aster Capital Management DIFC Ltd acquired a new position in shares of Soleno Therapeutics during the 3rd quarter valued at $37,000. Finally, Global Retirement Partners LLC boosted its position in Soleno Therapeutics by 519.0% during the 4th quarter. Global Retirement Partners LLC now owns 619 shares of the company’s stock worth $29,000 after purchasing an additional 519 shares during the period. 97.42% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Soleno Therapeutics

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Q4 results topped expectations: revenue of $91.7M and GAAP EPS of $0.80 beat consensus, supporting near-term confidence in sales execution and cash generation. Soleno Therapeutics, Inc. (SLNO) Revenue Tops Expectations With $91.7M in Q4 Results, TD Cowen Maintains Buy
• Positive Sentiment: HC Wainwright continues to rate SLNO “Buy” and raised several near-term EPS forecasts (Q1 and Q2 2026) and a bullish FY2027 view (analyst models show material earnings growth by 2027), which supports upside versus current levels and reinforces analyst conviction into the story. Analyst Comments / Street Insider
• Neutral Sentiment: HC Wainwright published a detailed set of quarterly and annual forecasts for 2026–2027 (multiple Qs and FY lines); these create a clearer roadmap for future earnings but are model-driven and carry execution risk—useful for positioning but not guaranteed.
• Negative Sentiment: At the same time, HC Wainwright trimmed several 2026 estimates (notably Q3 & Q4 2026 and FY2026 modestly) and lowered its price target from $120 to $100 — a reduction in near-term modeled upside even though the firm remains constructive. Benzinga Coverage Street Insider Coverage

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.